Views & Analysis
Market Access/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis
Philips on designing innovation and cultivating partnerships – part two
Jessica Hagen
collaboration, pharma, Philips, Philips Africa, Philips India
0 Comment
Market Access/ Views & Analysis/ Views and analysis
Global comparator data signal “alarm bells” for UK Government, says APBI
Amanda Barrell
ABPI, clinical trial recruitment, clinical trials, Life Sciences, UK life sciences, UK market access
0 Comment
Market Access/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis
Philips on designing innovation and cultivating partnerships – part one
Jessica Hagen
healthcare access, India, Philips India, Phillips, Sachin Grover, telehealth
0 Comment
Market Access/ Views & Analysis/ Views and analysis
The new European Unitary Patent system – What you need to know
mike.hammerton@pharmaphorum.com
European Union, European Unitary Patent system
0 Comment
Market Access/ Views & Analysis/ Views and analysis
As FDA inspections return, upholding compliance and maintaining GMP readiness is more crucial than ever
mike.hammerton@pharmaphorum.com
Dipti Gulati, fda, good manufacturing practice, NSF Health Sciences, Pharmaceutical Quality systems
0 Comment
Market Access/ Sales and Marketing/ Views & Analysis/ Views & Analysis/ Views and analysis
The big squeeze?
Leela Barham
Cancer Drugs Fund, NHS, NHS Digital, NHS spending
0 Comment
Market Access/ Oncology/ Views & Analysis/ Views & Analysis/ Views and analysis
Are timely access and robust safety mutually exclusive?
Amanda Barrell
EFPIA, ema, fda, Kristina Jenei, Oncology
0 Comment
Market Access/ Views & Analysis/ Views and analysis
Pharma’s post-pandemic launch performance problem: what’s the prognosis?
mike.hammerton@pharmaphorum.com
COVID-19, IQVIA, launch excellence, pandemic, Sarah Rickwood
0 Comment